Clinical Study
Imatinib Mesylate Effectiveness in Chronic Myeloid Leukemia with Additional Cytogenetic Abnormalities at Diagnosis among Black Africans
Table 3
Therapeutic and evolutionary features.
| Variables | Numbers (%) |
| Evolutionary phase | | Chronic phase | 18 (67) | Accelerated phase | 9 (33) | Hematologic remission | | Complete | 16 (59) | Partial | 11 (41) | Cytogenetic or molecular remission | | Major cytogenetic response (Ph+ ≤ 35%) | 14 (52) | Complete cytogenetic response (Ph+ 0%) | 7 (26) | Partial cytogenetic response (Ph+ 1%–35%) | 7 (26) | Minor cytogenetic response (Ph+ 36%–95%) | 8 (30) | Minimal cytogenetic response (Ph+ 96%–100%) | 4 (15) | Complete molecular response | 1 (3) | Outcome | | Alive | 17 (63) | Dead | 10 (37) | Causes of death | | Acutisation | 3 (30) | Hematologic toxicity | 4 (40) | Pulmonary tuberculosis | 1 (10) | Epilepsy | 1 (10) | Unspecified | 1 (10) | Adverse effects grade 3 and 4 | | Hematologic toxicity | | Anemia | 10 (37) | Leukopenia | 9 (33) | Thrombocytopenia | 8 (29) | Duration of follow-up (median and extreme values in months) | 37 (4–87) |
|
|